

I. AMENDMENT TO THE CLAIMS

Claims 1-30 (Canceled).

Claim 31. (Currently Amended) A method of ~~preventing or~~ reducing photodamage to skin cells of a subject comprising administering a composition comprising selegiline and/or desmethylselegiline to the subject in an amount effective to reduce apoptosis of skin cells exposed to electromagnetic or ionizing radiation.

Claim 32. (Previously added) The method of claim 31, wherein the composition is a topical composition.

Claim 33. (Previously added) The method of claim 32, wherein the topical composition is in a form selected from the group consisting of a cream, gel, transdermal patch, salve, lotion, and spray.

Claim 34. (Previously added) The method of claim 32, wherein the topical composition comprises selegiline at a concentration of between 1×10^{-11} moles/liter and 1×10^{-3} moles/liter.

Claim 35. (Previously added) The method of claim 32, wherein the topical composition comprises desmethylselegiline at a concentration of between 1×10^{-11} moles/liter and 1×10^{-3} moles/liter.

Claim 36. (Previously added) The method of claim 31, wherein the composition comprises desmethylselegiline in the form of its R(-) enantiomer and the S(+) enantiomer is substantially absent.

Claim 37. (Previously added) The method of claim 31, wherein the composition comprises desmethylselegiline in the form of its S(+) enantiomer and the R(-) enantiomer is substantially absent.

Claim 38. (Previously added) The method of claim 31, wherein the composition further comprises a diluent or carrier comprising one or more compounds selected from the group consisting of water, suspending agents, thickeners, humectants, preservatives, emollients, emulsifiers, and film formers.

- Claim 39. (Previously added) The method of claim 31, wherein the selegiline is administered as the free base.
- Claim 40. (Previously added) The method of claim 31, wherein the selegiline is administered as a pharmaceutically acceptable acid addition salt.
- Claim 41. (Previously added) The method of claim 31, wherein the desmethylselegiline is administered as the free base.
- Claim 42. (Previously added) The method of claim 31, wherein the desmethylselegiline is administered as a pharmaceutically acceptable acid addition salt.
- Claim 43. (Previously added) A method of treating a subject for photodamaged skin, wherein the photodamage results from exposure to electromagnetic or ionizing radiation, comprising administering a topical composition comprising selegiline and/or desmethylselegiline to the skin of the subject in an amount effective to reduce oxidative damage resulting from exposure to electromagnetic or ionizing radiation.
- Claim 44. (Previously added) The method of claim 43, wherein the topical composition is in a form selected from the group consisting of a cream, gel, transdermal patch, salve, lotion, and spray.
- Claim 45. (Previously added) The method of claim 43, wherein the topical composition comprises selegiline at a concentration of between 1×10^{-11} moles/liter and 1×10^{-3} moles/liter.
- Claim 46. (Previously added) The method of claim 43, wherein the topical composition comprises desmethylselegiline at a concentration of between 1×10^{-11} moles/liter and 1×10^{-3} moles/liter.
- Claim 47. (Previously added) The method of claim 43, wherein the topical composition comprises desmethylselegiline in the form of its R(-) enantiomer and the S(+) enantiomer is substantially absent.
- Claim 48. (Previously added) The method of claim 43, wherein the topical composition comprises desmethylselegiline in the form of its S(+) enantiomer and the R(-) enantiomer is substantially absent.

- Claim 49. (Previously added) The method of claim 45, wherein the topical composition further comprises a diluent or carrier comprising one or more compounds selected from the group consisting of water, suspending agents, thickeners, humectants, preservatives, emollients, emulsifiers, and film formers.
- Claim 50. (Previously added) The method of claim 45, wherein the selegiline is administered as the free base.
- Claim 51. (Previously added) The method of claim 45, wherein the selegiline is administered as a pharmaceutically acceptable acid addition salt.
- Claim 52. (Previously added) The method of claim 45, wherein the desmethylselegiline is administered as the free base.
- Claim 53. (Previously added) The method of claim 45, wherein the desmethylselegiline is administered as a pharmaceutically acceptable acid addition salt.